October 2024 – 2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO, has decided to step down from his role, effective October 31, 2024, to pursue other opportunities and dedicate more time to his family.
2bind expresses its sincere gratitude to Dr. Schubert for his significant contributions to the company’s success. His vision and leadership have been instrumental in establishing 2bind as a trusted partner for clients in the pharmaceutical and biotech industries.
Dr. Maximilian Plach, current Co-CEO, will continue to lead 2bind alongside Dr. Cosimo Kropp, who will be promoted from his position as Chief Business Officer to Co-CEO, effective November 1, 2024.
Dr. Plach, who joined 2bind in 2017, has been a driving force behind the company’s operational excellence and scientific leadership. He will oversee Operations, Development, and Technology. Dr. Kropp, who joined 2bind in 2021, has played a key role in expanding the company’s market presence and driving business growth. He will be responsible for Sales, Business Development, and Finance. Together, Dr. Plach and Dr. Kropp will share responsibility for Strategy and overall company direction.
“We are excited to embark on this new chapter with Maximilian and Cosimo at the helm,” said Prof. Dr. Gernot Längst, founder of 2bind and board member. “Their combined expertise, leadership skills, and deep understanding of the industry make them the ideal team to guide 2bind into the future.”
“We thank Thomas for his dedication and wish him all the best in his future endeavors,” added Prof. Dr. Ralf Wagner, 2bind board member and founder of Geneart AG (now part of Thermofisher). “We are confident that Maximilian and Cosimo will continue to build on 2bind’s strong foundation and drive further innovation and growth.”